drugset / Trial / NCT07385664
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
NaSingle-groupOpen-labelTreatment
Summary
This study was a single-arm, two-cohort, phase II trial aimed at evaluating the efficacy and safety of FAPI-PET/CT response for guiding the selection of neoadjuvant treatment modes after chemotherapy combined with immunotherapy.
Timeline
- Start
- 2026-01-28
- Primary completion
- 2027-01-30
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |